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We have studied the role of the N-terminal extracellular domain of the human immunodeficiency virus type 1 (HIV-1)
coreceptor, CXCR-4, in the entry and fusion of syncytium-inducing strains of HIV-1. Progressive deletions were introduced
in the N-terminal extracellular domain of CXCR-4 and the effect on infection by different isolates was tested. Infection
of cells expressing the different CXCR-4 deletion mutants by HIV-1 LAI and 89.6 was reduced only about twofold. In
contrast, the HIV-1 GUN-1 and RF isolates were substantially more impaired in their ability to mediate cell-free infection
and cell –cell fusion. Since LAI and RF are T-cell line-tropic viruses while 89.6 and GUN-1 are dual tropic, no clear
correlation between tropism and requirements for CXCR-4 N-terminal sequences emerged. We also introduced point
mutations at the two N-linked glycosylation sites. The isolates tested (LAI, RF, GUN-1, and 89.6) were not affected by
the removal of predicted N-linked glycosylation sites in CXCR-4. We conclude that distinct virus strains interact differently
with the CXCR-4 coreceptor and that the N-terminal extracellular domain is not the sole functional domain important for
HIV-1 entry. q 1997 Academic Press
INTRODUCTION isolates, including CCR-3 and CCR-2b (Choe et al., 1996;
Doranz et al., 1996). Furthermore, some isolates (TCLA
Human immunodeficiency virus type 1 (HIV-1) enters
or primary) were termed dual tropic because they can
the cell following fusion of the virion and cell membranes
infect both T cells and macrophages (Collman et al.,(Maddon et al., 1988; McClure et al., 1988; Stein et al.,
1992; McKnight et al., 1995). These isolates are able to1987). This process is initiated by the high-affinity binding
use either CXCR-4 or CCR-5 as coreceptor (Dittmar etof the gp120 subunit of the envelope glycoprotein (Env)
al., 1997; Doranz et al., 1996; Simmons et al., 1996). Theto the CD4 molecule (Moore et al., 1993; Signoret et al.,
exact mechanism by which CXCR-4 and CCR-5 promote1993; Weiss, 1993). For fusion to be completed additional
the entry of HIV-1 into CD4-expressing cells is currentlycell surface molecules or coreceptors are required
unknown.(Chesebro et al., 1990; Clapham et al., 1991; Dragic et
In this study, we investigated the role of the N-terminalal., 1992; Maddon et al., 1986). Depending on the virus
extracellular domain of CXCR-4 in HIV-1 entry. The N-isolates studied these coreceptors are different. The
terminal domain in both the CXC and the CC chemokineseven-transmembrane G protein-coupled chemokine re-
receptor families is likely to contain the primary high-ceptors CXCR-4 [previously known as LCR-1, LESTR,
affinity binding site for chemokine ligands (Murphy, 1994;HUMSTR, or fusin (Federsppiel et al., 1993; Feng et al.,
Premack and Schall, 1996; Wells et al., 1996). Moreover,1996; Herzog et al., 1993; Jazin et al., 1993; Loetscher et
chemokines can block HIV-1 infection. In particular, stro-al., 1994; Nomura et al., 1993)] and CCR-5 (Combadiere
mal cell-derived factor-1 blocks infection of TCLA strainset al., 1996; Raport et al., 1996; Samson et al., 1996) act
that use CXCR-4 as a coreceptor (Bleul et al., 1996; Ober-as coreceptors for the entry of syncytium-inducing (SI),
lin et al., 1996), and RANTES, macrophage inflammatoryT-cell line-adapted (TCLA) isolates (Feng et al., 1996)
protein (MIP)-1a, and MIP-1b block infection of CCR-5-and primary non-syncytium-inducing (NSI) macrophage-
using primary viruses on CD4/ CCR-5/ cells (Alkhatib ettropic strains, respectively (Alkhatib et al., 1996; Deng et
al., 1996; Cocchi et al., 1995, 1996; Deng et al., 1996;al., 1996; Dragic et al., 1996). Additional members of the
Dragic et al., 1996; Jansson et al., 1996). Furthermore, itchemokine receptor family can be used by some HIV-1
has recently been shown that gp120 can compete for
MIP-1a and MIP-1b binding to CCR-5 (Trkola et al., 1996;
1 To whom correspondence and reprint requests should be ad- Wu et al., 1996). Finally, anti-serum raised against a pep-dressed. Fax: /44 (0) 171 352 3299. E-mail: laurent@icr.ac.uk.
tide corresponding to the N-terminal part of CXCR-4 was2 Present address: Aaron Diamond AIDS Research Center, 455 First
Ave., New York, NY 10016. able to block infection and cell–cell fusion of TCLA iso-
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lates of HIV-1 (Feng et al., 1996) and the formation of washed and split in 96-well (or 48-well) plates in tripli-
cate. Transfected cells were challenged 24 hr later witha ternary complex between gp120, CD4, and CXCR-4
(Lapham et al., 1996). We report here that N-terminal 500–1000 infectious units of HIV per well (as titrated on
HeLa-CD4-LTRLacZ cells) for 24 hr. Each construct wassequences required for HIV-1 infection depends on the
HIV-1 isolate tested. transfected in parallel with the wild-type CXCR-4 recep-
tor. HIV infectivity for each mutated receptor was there-
fore compared to infectivity estimated on the wild-typeMATERIAL AND METHODS
CXCR-4 receptor. Viral titers on the transfected cells were
Cell lines and viruses compared with titers on HeLa-CD4 cells to control for
variation in transfection efficiency. Transfection effi-U373-CD4-LTRLacZ cells, astroglioma cells stably
ciency was estimated by transfection of a Tat-expressingtransfected with human CD4 and a LTRLacZ construct,
vector in LTRLacZ cells. For U373-CD4-LTRLacZ a simpleand the cat kidney CCC/CD4 cell line were all maintained
X-Gal assay was performed as described previouslyin DMEM (Gibco) supplemented with 10% fetal calf serum
(Dragic, et al., 1995) and the blue-stained foci were(FCS) and antibiotics. These cell lines have all been pre-
counted 48 hr postinfection. In LTRLacZ cells, HIV-1 in-viously described (Clapham et al., 1991; Harrington and
fection results in Tat production that stimulates the tran-Geballe, 1993).
scription of the LTRLacZ transgene and in the accumula-The T-cell line-adapted viruses RF, LAI, and GUN-1
tion of b-galactosidase. For CCC/CD4 the cells were im-have been previously described (Popovic et al., 1984;
munostained 3 days postinfection using an anti-p24Takeuchi et al., 1991; Wain-Hobson et al., 1991). HIV-
antibody as the primary antibody and subsequently a1GUN-1 is a dual-tropic isolate (McKnight et al., 1995) that
secondary antibody conjugated to b-galactosidase ascan infect macrophages as well as T-cell lines. The virus
previously described (Clapham et al., 1992). The blue-stocks were prepared by cocultivation with H9 cells. The
stained foci were scored after a X-Gal assay. For fusioncorresponding H9 chronically infected cell lines were
assay between U373-CD4-LTRLacZ and chronically in-maintained in RPMI medium supplemented with 10% FCS
fected H9 cells, the same procedure was followed.and antibiotics. The dual-tropic primary isolate virus 89.6
(Collman et al., 1992), a gift from R. Collman, was propa-
gated on PBMCs. All virus stocks were titrated on HeLa- RESULTS
CD4-LTRLacZ cells (Clavel and Charneau, 1994) that
In order to study the role of the N-terminal domainwere a gift from M. Alizon (ICGM, Paris). For GUN-1 and
of CXCR-4, we used the polymerase chain reaction to89.6, viral stocks were plated on primary macrophages
generate three mutants deleted for the N-terminal se-to assess their dual tropism (Dittmar et al., 1997;
quences: LN1, LN2, and LN3 are truncated for 7, 15, andMcKnight et al., 1997; Simmons et al., 1996).
23 amino acids, respectively (Table 1). We also used PCR
and site-directed mutagenesis to mutate each of the twoFlow cytometry analysis of surface expression
putative N-linked glycosylation sites in CXCR-4. One of
Each of the mutated CXCR-4 constructs or pcDNA3 these sites is located in the N-terminal extracellular do-
vector (mock) were transfected by the calcium phosphate main (N11), the other is located in the second extracellu-
precipitation method into U373-CD4-LTRLacZ cells for lar loop (N176). They were respectively converted to an
16–20 hr (10 mg/100-mm petri dish). The medium was isoleucine (LG1) and glutamine (LG2) or both were mu-
removed and the cells were incubated for another 12 hr. tated (LG1G2) (Table 1). The constructs were tagged at
Cells were then trypsinized, stained with the 12G5 anti- the C-terminus with the myc epitope (9E10) (Evan et al.,
CXCR-4 monoclonal antibody (Endres et al., 1996) or with 1985) and cloned into pcDNA3 (Invitrogen, The Nether-
an isotype control (IgG2a; Sigma Immunochemicals), and lands). We also included RM3, a differentially spliced
subsequently with fluorescein isothiocyanate (FITC)-con- variant of CXCR-4 (in pRcCMV; Invitrogen) which has the
jugated rabbit anti-mouse immunoglobulin antibodies 5 N-terminal amino acids substituted for 10 different ones
(Dako). The cells were then analyzed and the data col- (Table 1).
lected on a Becton–Dickinson FACScan. To determine Surface expression of the different mutants was esti-
the percentage of positive cells, a marker was set up at mated after transfection in two different cell types: cat
a position that gives a reading of 2% of positive cells for kidney CCC cells and U373-CD4-LTRLacZ cells. We
the mock-transfected cells. used two monoclonal antibodies to assess cell surface
expression of the different CXCR-4 mutants. The 9E10Infectivity and fusion assays
monoclonal antibody (MAb) recognized the C-terminal
myc-tag by immunofluorescence of permeabilized cellsThe U373-CD4-LTRLacZ or CCC/CD4 were plated in
12-well plates (or 60-mm petri dishes) and transfected (data not shown) while the 12G5 MAb, specific for
CXCR-4 (Endres et al., 1996), detected the CXCR-4 de-the next day using the calcium phosphate precipitation
method for 16–20 hr with 1 or 5 mg DNA per well. The rivatives by flow cytometry (Fig. 1). 12G5 blocks HIV-1
infection in a cell-type and virus-specific mannertransfection medium was then removed, and the cells
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TABLE 1
Sequences of CXCR-4 N-Terminal Deletion Mutants and Glycosylation Mutants
N-terminal extracellular domain
CXCR-4 MEGISIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTG
RM3a MSIPLPPLLQIYTSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTG
LN1 MSDNYTEEMGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTG
LN2 MGSGDYDSMKEPCFREENANFNKIFLPTIYSIIFLTG
LN3 MKEPCFREENANFNKIFLPTIYSIIFLTG
Glycosylation sites
LG1 N11I
LG2a N176Q
LG1G2a N11I and N176Q
Note. The putative first transmembrane segment is in boldface.
a These constructs do not contain the myc tag at the C-terminus.
(McKnight et al., 1997). The precise location of the 12G5 The CXCR-4 mutants were tested for sensitivity to HIV-
1 infection. Each construct was transiently transfectedepitope is currently unknown; however, the N-terminus
of CXCR-4 does not appear to be required for 12G5 into CCC/CD4 or into U373-CD4-LTRLacZ cells and chal-
lenged 24 hr later with different CXCR-4-using SI HIV-1binding (Julie Davis Turner, personal communication).
The mutated receptors were expressed at the cell sur- strains. HIV-1 strains tested were LAI, RF, GUN-1, and
89.6. LAI and RF are TCLA strains that use CXCR-4 asface of U373-CD4-LTRLacZ cells and CCC cells. Figure
1 shows that CXCR-4 was expressed on about 60% of a coreceptor, whereas GUN-1 and 89.6 are dual-tropic
strains that infect primary macrophages as well as T-cellU373-CD4-LTRLacZ, LN1 on 50%, LN2 on 15%, LN3 on
40%, LG1G2 on 45%, and RM3 on 15% cells as esti- lines (Collman et al., 1992; McKnight et al., 1995), using
either CCR-5 or CXCR-4 (Dittmar et al., 1997; Doranz etmated by 12G5 staining. Immunofluorescence of mem-
brane-associated staining with 9E10 correlated with al., 1996; Simmons et al., 1996). Table 2 and Fig. 2 show
infectivity titers for these virus strains tested on CCC/12G5 surface expression (not shown), indicating that
the lower levels of expression for some constructs, as CD4 and U373-CD4-LTRLacZ, respectively, after trans-
fection of appropriate plasmid DNA encoding each N-determined by flow cytometry, were not due to modifi-
cation of the 12G5 epitope. The LG1 and LG2 receptors terminal deleted CXCR-4 construct. LAI infectivity was
only slightly reduced when changing the first N-terminalhad the same level of expression as LG1G2 and wild-
type CXCR-4 (not shown). amino acids (RM3) or when progressively truncating the
FIG. 1. Flow cytometry analysis of CXCR-4 mutant cell surface expression. Transiently transfected U373-CD4-LTRLacZ cells were first stained
using either an isotype control (IgG2a, Kappa; Sigma Immunochemicals) (filled histogram) or the 12G5 MAb (open histogram) and subsequently
with an anti-mouse FITC-conjugated secondary antibody (Dako). Data were collected and analyzed on a Becton–Dickinson FACScan.
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TABLE 2 be glycosylated, we tested the role of N-linked glycosyla-
tion of CXCR-4 in HIV-1 entry. CXCR-4 contains two po-Infection of Transiently Transfected CCC/CD4 Cells
tential N-glycosylation sites, one in the N-terminal extra-with Different CXCR-4 Mutantsa
cellular domain, the other in the second extracellular loop
HIV-1 isolate (Loetscher et al., 1994). Berson et al. showed that at least
one of the two sites in CXCR-4 is likely to be glycosylated
Construct LAI RF GUN-1
(Berson et al., 1996). We mutated these putative glycosyl-
ation sites, either individually (LG1 and LG2) or togetherMock 0 0 0
CXCR-4 93 { 12b 105 { 10 54 { 5 (LG1G2) and studied the capacity of the resulting mole-
LN1 99 { 4 59 { 6 2 { 1 cules to confer HIV-1 entry. For all the isolates tested
LN2 45 { 1 8 { 2 0 (LAI, RF, GUN-1, and 89.6), mutation of predicted sites for
LN3 34 { 3 5 { 2 0
N-linked glycosylation did not affect the ability of CXCR-4
to function as an HIV-1 coreceptor in either CCC/CD4a After transfection the CCC/CD4 cells were challenged with different
isolates and immunostained for p24 accumulation 3 days postinfection (data not shown) or U373-CD4-LTRLacZ (Table 3).
(Clapham et al., 1992).
b Number of blue-stained foci/well (mean { SD). The experiment DISCUSSION
presented is representative of two done in triplicate.
The chemokine receptor CXCR-4 is used as a corecep-
tor for entry of primary SI and T-cell line-adapted strainsN-terminal domain of CXCR-4. In contrast, GUN-1 titers
of HIV-1 in otherwise nonpermissive CD4/ cells (Fengwere severely reduced on all the deletion mutants, and
on CCC/CD4 cells no foci at all were observed when the
deletion was as short as 15 amino acids (LN2) (Table 2
and Fig. 2A). Even minor changes in the amino-terminal
region of CXCR-4 (RM3) had a marked effect on the ability
of GUN-1 to enter cells, but little effect on LAI. Unlike
LAI, RF infectivity was more severely reduced by the N-
terminal deletions while that of 89.6 was barely influ-
enced (Table 2 and Fig. 2B). There was no evidence that
the CD4/ target cell affects coreceptor function, since
similar infectivity results were obtained with CCC/CD4
and U373-CD4-LTRLacZ. These results indicate that the
CXCR-4 requirements are different for distinct HIV-1 iso-
lates. Furthermore, these different requirements do not
correlate with the cell tropism of the considered isolate:
LAI and RF are T-cell tropic, whereas GUN-1 and 89.6
are dual tropic.
We tested whether cell –cell fusion was also affected
by truncation of the N-terminus of CXCR-4. Cell–cell fu-
sion was measured using U373-CD4-LTRLacZ cells as
target cells. Syncytium formation between these cells
and HIV-1-chronically infected cells results in Tat-in-
duced transactivation of the LTRLacZ transgene and can
be easily detected by an X-Gal assay. When we coculti-
vated H9 cells chronically infected with LAI or GUN-1
with transfected U373-CD4-LTRLacZ cells the same pat-
tern of results was observed: H9/LAI readily formed syn-
cytia with cells expressing CXCR-4 or the different mu-
tants (RM3, LN1, LN2, or LN3). In contrast, and as ex-
pected from the cell-free virus infection experiments, H9/
GUN-1 cells were severely affected by these N-terminal
deletions and by the N-terminal substitution (RM3), losing
80–90% of their ability to fuse (data not shown). Thus,
FIG. 2. Infection of cells expressing different CXCR-4 mutants. Tran-the N-terminal extracellular domain of CXCR-4 and espe-
siently transfected U373-CD4-LTRLacZ cells were challenged with dif-cially the first 10 amino acids play a role in HIV-1 entry
ferent HIV-1 isolates (RF, LAI, GUN-1, or 89.6) 24 hr after transfection.
and fusion, as recently reported by others for CCR-5 Blue-stained cells were scored 48 hr later after an X-Gal assay. The
(Rucker et al., 1996). background foci detected on untransfected cells were substracted from
the values.Since, the N-terminal extracellular domain is likely to
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TABLE 3 mediate LAI infection at the same level. Our results indi-
cate that different HIV-1 isolates must interact withInfection of Transiently Transfected U373-CD4-LTRLacZ Cells
CXCR-4 in different ways during entry into CD4/ CXCR-with CXCR-4 Glycosylation Mutantsa
4/ cells. Interestingly, there was no correlation between
HIV-1 isolate T-cell or dual tropism; therefore, the differences observed
here do not result from the capacity of the dual-tropic
Construct LAI RF GUN-1 89.6
viruses to use CCR-5 as well as CXCR-4, compared to
TCLA strains that use CXCR-4 but not CCR-5 (SimmonsMock 0 0 0 0
CXCR-4 252/286b 272/285 254/242 238/210 et al., 1996). It has been reported that the N-terminal
LG1 157/177 192/163 124/138 147/210 extracellular domain of CCR-5 is important for determin-
LG2 473/502 227/332 267/304 316/371
ing coreceptor specificity and that different isolates areLG1G2 239/348 283/302 197/159 257/273
dependent on different residues in the N-terminal extra-
a After transfection U373-CD4-LTRLacZ cells were challenged with cellular domain (Rucker et al., 1996). In particular, macro-
different isolates and blue-stained foci counted after an X-Gal assay. phage-tropic viruses were dependent on residues 2–5
b Results are from duplicate wells. Background foci estimated on while the dual-tropic 89.6 isolate required residues 6–9
untransfected cells were substrated from the values.
of CCR-5 for efficient fusion. Furthermore, it indicates
that 89.6 requires the N-terminal domain of CCR-5 but the
et al., 1996; Zhang et al., 1996). In this study we showed equivalent region in CXCR-4 is dispensable for efficient
that distinct HIV-1 isolates have different requirements infection.
for interaction with the CXCR-4 coreceptor. It has been reported that the gp120 subunit of Env
By mutating the two potential glycosylation sites lo- binds to the coreceptor in a gp120/CD4/coreceptor ter-
cated in the N-terminal region and in the second extracel- nary complex on the cell surface during the entry process
lular loop, we showed that none of the four isolates and can compete for MIP-1a and MIP-1b binding to CCR-
tested (LAI, RF, GUN-1, and 89.6) were affected by lack 5 (Lapham et al., 1996; Trkola et al., 1996; Wu et al., 1996).
of N-linked glycosylation. Glycosylation does not seem
Furthermore, the specificity for different coreceptors and
to be required for the other major coreceptor CCR-5,
inhibition of HIV-1 entry by CC chemokine has been
either (Rucker et al., 1996). Binding of the 12G5 mono-
mapped to a region that includes the V3 domain of gp120
clonal antibody specific for CXCR-4 was not affected by
(Choe et al., 1996; Cocchi et al., 1996; Jansson et al.,loss of glycans, meaning that the glycosylation state of
1996; Trkola et al., 1996; Wu et al., 1996). It is thereforethe receptor is not important for 12G5 recognition.
likely that viruses with divergent V3 loops (e.g., LAI andBy constructing deletion mutants of CXCR-4 and test-
GUN-1) will interact with the CXCR-4 molecule differently.ing them in cell-free virus infection and cell-fusion in two
Furthermore, there is evidence that an antiserum againstdifferent CD4/ cell lines, we found that different isolates
the N-terminal domain of CXCR-4 partially blocks HIVhave different dependency on N-terminal sequences. De-
infection, syncytium formation, and ternary complex for-leting as few as 7 amino acids (LN1) or replacing the
mation (Feng et al., 1996; Lapham et al., 1996). We antici-first 5 amino acids by 10 different ones abolished GUN-
pate that gp120 from GUN-1 and RF will be dependent1 entry and syncytium-forming ability with little effect on
upon an interaction with the N-terminal domain while forLAI and 89.6 isolates. RF entry was less affected by these
other isolates like LAI and 89.6, this interaction is eitherchanges in CXCR-4 but was dramatically reduced by fur-
dispensable or does not take place during the entry pro-ther deletion of the N-terminal extracellular sequences
cess. A number of studies have shown that the in vivo NSI(LN2 and LN3). The complete removal of the N-terminal
to SI phenotypic switch is associated with an increase inextracellular domain of CXCR-4 has not been studied in
the net charge of the V3 loop (Callahan, 1994; Cheng-the present work but it has been recently shown that a
Mayer et al., 1991; Fouchier et al., 1992; Kuiken et al.,construct deleting the 36 amino acids of the N-terminus
1992), which also correlates with the capacity of SI vi-was still functional for LAI entry and fusion while being
ruses to use CXCR-4 instead of, or in addition to, CCR-nonfunctional for other isolates (A. Brelot, N. Heveker,
5 (Jansson et al., 1996). Since SI isolates accumulateand M. Alizon, personal communication). It is thus ex-
positively charged residues in the V3 loop while gainingpected that this deletion mutant will not be functional for
CXCR-4 coreceptor usage, we suggest that the V3 loopentry of GUN-1 and RF strains. Furthermore, since these
net charge of different viruses will affect their interactiondeletion mutants still function for entry of some isolates,
with the negatively charged N-terminal extracellular do-it is likely they are properly expressed, folded, and trans-
main. By progressively deleting the N-terminal domain,ported to the cell surface.
the net charge of the N-terminus is increased (from 06All the deletion mutants of CXCR-4 tested were ex-
for LN1 to 0 for LN3). Interestingly, LAI and 89.6 V3 loopspressed on the cell surface albeit at different levels. The
are slightly more positive (/9 and /7, respectively) thanlower levels of expression of some deleted receptors
RF and GUN-1 V3 loop sequences (/6 and /5, respec-(especially for LN2) cannot account for the differences
observed in HIV-1 infectivity, since LN2 and LN3 still tively). However, this simple model does not take into
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cell lines: Induction and enhancement by sCD4. J. Virol. 66, 3531–account the probable role of other regions of CXCR-4
3537.and gp120 in HIV-1 entry.
Clavel, F., and Charneau, P. (1994). Fusion from without directed by
The N-terminal region studied here is not the sole human immunodeficiency virus particles. J. Virol. 68, 1179–1185.
domain necessary for CXCR-4 to function as a HIV-1 Cocchi, F., DeVico, A. L., Garzino-Demo, A., Arya, S. K., Gallo, R. C., and
Lusso, P. (1995). Identification of RANTES, MIP-1a, and MIP-1b ascoreceptor. Not all the isolates studied were inhibited by
the major HIV-suppressive factors produced by CD8/ T cells. Sci-N-terminal truncations indicating that another region(s)
ence 270, 1811–1815.is likely to be involved as well. Furthermore, HIV-1 entry
Cocchi, F., DeVico, A. L., Garzino-Demo, A., Cara, A., Gallo, R. C., and
is inhibited by the 12G5 anti-CXCR-4 monoclonal anti- Lusso, P. (1996). The V3 domain of the gp120 envelope glycoprotein
body that binds to each of our constructs and thus must is critical for chemokine-mediated blockade of infection. Nat. Med.
2, 1244–1247.interact with an epitope away from the N-terminus. The
Collman, R., Balliet, J. W., Gregory, S. A., Friedman, H., Kolson, D. L.,other region(s) of CXCR-4 implicated in HIV-1 entry re-
Nathanson, N., and Srinivasav, A. (1992). An infectious molecularmains to be determined.
clone of an unusual macrophage-tropic and highly cytopathic strain
The precise mechanism by which HIV-1 uses CXCR- of human immunodeficiency virus type 1. J. Virol. 66, 7517–7521.
4, in conjunction with CD4, to gain entry into cells is still Combadiere, C., Ahuja, S. K., Lee Tiffany, H., and Murphy, P. M. (1996).
Cloning and functional expression of CC CKR5, a human monocyteunknown. Other mutations and chimeras between CXCR-
CC chemokine receptor selective for MIP-1a, MIP-1b, and RANTES.4 and inactive nonhuman counterparts will further define
J. Leukocyte Biol. 60, 147–152.regions of the molecule used by HIV-1 to infect
Deng, H., Liu, R., Elmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di
CD4/cells. Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper,
S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996). Identifica-
tion of a major co-receptor for primary isolates of HIV-1. Nature 381,ACKNOWLEDGMENTS
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